News | May 24, 2025
Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr
For the full year FY25, net profit soared 12x to Rs 345 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Subscribe To Our Newsletter & Stay Updated
